Compare CVS Health Corp (CVS) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Marqeta Inc — how do they compare? CVS Health Corp trades at $86.25 (market cap $112.49B), while Marqeta Inc trades at $17.36 (market cap $1.78B). The key difference: CVS Health Corp is far larger — about 63.2× Marqeta Inc's market cap, and CVS Health Corp pays a 3.02% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Marqeta Inc for 44 Days on average.
| CVS | MQ | |
|---|---|---|
Market Cap | $112.49B | $1.78B |
Volume | 8,467,392 | 1,087,097 |
Sector | Health | Technology |
52-Week High | $110.60 | $20.32 |
52-Week Low | $70.08 | $15.04 |
Typical Hold Time | 83 Days | 44 Days |
Enterprise Value | $174.83B | $1.09B |
Dividend Yield | 3.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.80, up 1.59% today, with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 27% upside. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.87 estimate. Revenue growth remains solid, reaching $402.07B in 2025, though net margins compressed to 1.18%. The technical picture shows bullish momentum with current price near key support at $87.
CVS presents a compelling value opportunity with attractive valuation multiples (P/E 23.21, P/S 0.27) and dividend stability, but faces margin pressure from healthcare cost trends. The stock's upside depends on maintaining earnings momentum amid reimbursement challenges and regulatory scrutiny highlighted in recent legal investigations.
Marqeta (MQ) trades at $17.44, up 5.38% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with three consecutive quarterly EPS beats and positive cash flow trends, though valuation remains elevated with a P/E of 189.56. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives.
While technical indicators suggest near-term strength, the stock faces fundamental challenges with negative net income and high valuation multiples. Analyst consensus is cautious with a $11.38 price target below current levels, indicating 31.82% buy ratings. Key risks include contract renewals in Q3 2026 and growth moderation expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
